📦Cambrex High Point's Application for Controlled Substances Import
Cambrex High Point, Inc., has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Learn More📄USPTO Seeks Comments on Invention Promoters Complaint Process
The United States Patent and Trademark Office (USPTO) will submit the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. The USPTO invites comments on this information collection renewal of 0651-0044 (Complaints Regarding Invention Promoters), which helps the USPTO assess the impact of its information collection requirements and minimize the public's reporting burden. Public comments were previously requested via the Federal Register on May 19, 2025, during a 60-day comment period (90 FR 21295) This notice allows for an additional 30 days for public comment.
Learn More💊Vici Health Sciences' Import Application for Controlled Substances
Vici Health Sciences, LLC. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Learn More🦴FDA Classifies Orthopedic Surgical Instruments as Class II Devices
The Food and Drug Administration (FDA, the Agency, or we) is classifying orthopedic manual surgical instrumentation for use with total disc replacement devices into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of orthopedic manual surgical instrumentation for use with total disc replacement devices. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Learn More📈SEC Designates Longer Time for Cboe Rule Change on Canary XRP Trust
The Securities and Exchange Commission has extended the period to consider a proposed rule change by Cboe BZX Exchange for listing and trading shares of the Canary XRP Trust. The decision aims to allow sufficient time for careful consideration of the proposal and the issues it raises within the regulatory framework for cryptocurrency.
Learn More📋CMS Public Comment Notice on Information Collection Activities
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, and to allow a second opportunity for public comment on the notice. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
Learn More✈️Proposed Airworthiness Directive for ATR Airplanes
The FAA proposes to adopt a new airworthiness directive (AD) for certain ATR--GIE Avions de Transport R[eacute]gional Model ATR42- 300, -320, -500, ATR72-201, and -212A airplanes, and for all ATR--GIE Avions de Transport R[eacute]gional Model ATR72-102, -202, -211, and - 212 airplanes. This proposed AD was prompted by an inspection on the ATR final assembly line that found a fire extinguishing tube, located on the ceiling of the aft cargo compartment, disconnected from its sleeve. This proposed AD would require a functional check of the aft cargo fire extinguishing system and applicable on-condition actions, if necessary. For certain airplanes, this proposed AD would also require an additional functional check and applicable on-condition actions. The FAA is proposing this AD to address the unsafe condition on these products.
Learn More⚡Regulatory Notice for Ranchland Solar
The Department of Energy has issued a notice regarding an investigation into Ranchland Solar, LLC's Rate Schedule under the Federal Power Act. The proceeding, initiated under section 206, will assess whether the rate schedule is unjust or discriminatory, and it includes details on filing interventions and accessing documentation.
Learn More💧PacifiCorp Withdrawal of Water Quality Management Plan Notice
The Department of Energy's notice details the effectiveness of PacifiCorp's withdrawal of its Water Quality Management Plan for the North Umpqua Hydroelectric Project. This withdrawal, which faced no opposition, results in the termination of the proceeding as per Commission rules, marking a significant regulatory action in energy project management.
Learn More🦠FDA Classifies Multiplex Respiratory Panel for Respiratory Pathogens
The Food and Drug Administration (FDA, the Agency, or we) is classifying the multiplex respiratory panel to detect and identify emerging respiratory pathogen(s) and common respiratory pathogens in human clinical specimens into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the multiplex respiratory panel to detect and identify emerging respiratory pathogen(s) and common respiratory pathogens in human clinical specimens. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Learn More